AceLink Therapeutics kickstarts Phase 2 Fabry disease clinical trials in China
In a pivotal move, AceLink Therapeutics, Inc., a frontrunner in the biopharmaceutical sector, has inaugurated its first clinical trial site in China. The Phase 2, open-label study aims to gauge the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary physiological efficacy measures of AL01211 for untreated classic Fabry disease males. A vanguard in the field, AceLink […]